



Featured Research: CYNO, HSP, REGN, WCG

Initiations: None | **Rating Changes:** None | **Price Target Changes:** HSP | **Estimate Changes:** HSP, REGN
| **MEDACorp:** None

Reference Tools:

[Catalyst Tracker](#) | [Calendar of Events](#) | [HC Conferences](#) | [Earnings Rundown](#) | [Abbreviations & Acronyms](#) | [Leerink Events](#)

Leerink Events - Please contact your Leerink Partners representative for details

LEERINK GLOBAL HEALTHCARE CONFERENCE

February 12-13, 2014

February 13

KEYNOTE SPEAKER at noon

Mark McClellan, M.D., Ph.D.

PANEL DESCRIPTIONS

HEALTHCARE SERVICES – 9:20am

Exchanges' Brave New World: Will They Be the Amazon of American Healthcare?

Ana Gupte, Ph.D., Moderator

IMMUNO-ONCOLOGY – BIOPHARMA – 9:20am

Immuno-Oncology: The Future of Cancer Treatment is Now

Seamus Fernandez, Howard Liang, Ph.D., Michael Schmidt, Ph.D., Co-Moderators

HEALTHCARE TECHNOLOGY & DISTRIBUTION at 4:00pm

The Future of HCIT Population Health in an Increasingly Digital World

David Larsen, CFA, Moderator

RESPIRATORY GENERICS – SPECIALTY PHARMACEUTICALS at 4:00pm

Here Come Respiratory Generics, a New Product Class and Opportunity

Jason Gerberry, JD, Moderator

Companies in coverage universe presenting today: ACHN, ACOR, AFFX, AGIO, AMRN, ANTH, BMRN, CLVS, CNC, CPHD, CPSI, CYNO, DXCM, ELOS, ENTA, FOLD, HPTX, HRTX, HTWR, IDIX, IMGN, ISIS, KBIO, KPTI, LMNX, MNK, MRTX, NVS, OMED, ONTX, OREX, OVAS, PODD, RCPT, RIGL, RNA, SGEN, SIAL, SNSS, SYK, THRX, TSRO, UNIS, VICL, XNCR

Contact your Leerink representative for details.

2/14: Corporate Access: Thermo Fisher Scientific Inc: TMO, Boston

2/19: Corporate Access: Cigna Site Visit: CI, Connecticut

2/19: MEDACorp Pulse Call: HIMSS Preview – Vendor Insights from a Leading HCIT Specialist, Boston, 10:00AM EST

Today's Healthcare Events

Company Events: MOH Investor Day

Medical Meetings: International Stroke Conference; Advances in Genome Biology and Technology

Today's Research

Hospira, Inc. (HSP) | Jason M. Gerberry, JD

Mfg Issues Moving in Right Direction, but Little Impact to Our Ests

Market Perform | **Market Cap:** \$7,404.7M | **Price:** \$44.26 | **Price Target:** \$45.00 → \$46.00 | **Methodology:** ~20x '15E EPS of \$2.34

• **Bottom Line:** We are modestly changing our ests reflecting 4Q results. Overall, we came away with a few positive takeaways from the quarterly update, mainly that US SIP had another strong qtr outpacing our ests by ~\$30m, and the change of Rocky Mt/Austin facilities to VAI status improves the outlook for new product contribution in 2014. Overall, the mfg quality issues appear to be moving in the right direction with a pending inspection at Rocky Mt (est. mid-2014); the facility has been running at normalized capacity. We remain MP as we're bearish on the market opportunity for biosimilars and the ultimate profitability of those assets, which we believe are drivers of HSP's premium multiple. Our \$46 price target (from \$45) is based on ~20x our now higher '15E \$2.34 EPS.

- Updates on Rocky Mt/Austin provide a "psychological positive" for HSP, but also improve outlook for US pipeline contribution.
 - Precedex genericization the main delta in 2014 guidance.
 - No major biosimilar updates in the qtr; we remain bearish on market/profitability.
 - **2014E EPS/REV:** \$2.19 / \$4,216.0 → \$2.12 / \$4,333.0
 - **2015E EPS/REV:** \$2.26 / \$4,433.0 → \$2.34 / \$4,433.0
- Revenues in MM; EPS includes stock compensation expense.*

Cynosure, Inc. (CYNO) | Richard Newitter

Solid 4Q Sales/EPS Beat

Outperform | **Market Cap:** \$447.2M | **Price:** \$27.66 | **Price Target:** \$36.00

• **Bottom Line:** CYNO reported solid above-expectations 4Q results highlighted by a \$6.7M sales beat vs. consensus (+\$4.7M vs. us) and \$0.39 EPS, which was +\$0.18 above our \$0.21 est. Op. margin came in at 16% vs. our ~9% estimate. The sales/EPS outperformance was solid even when adjusting for ~\$4M of royalty revenue booked this quarter from the Tria settlement. Excluding Tria revenue, sales were still ahead of the Street by \$2.7M, and we estimate op. margin and EPS would have been ~12% and \$0.26, respectively. Going forward, we note that Tria will result in a 3% ongoing royalty revenue stream for CYNO (we estimate \$1-2M/yr) and likely will also include additional 1x payments in 2014 to the tune of ~\$6M. **We expect the shares to react positively to these strong results.** Conference Call at 9:00 A.M. EST. Dial-In: (877) 709-8155.

- Sales Beat...
- and EPS Ahead of Us by +\$0.18 (+~\$0.05 ex-Tria settlement benefit).
- Published 2.12.14.

Regeneron Pharmaceuticals, Inc. (REGN) | Joseph P. Schwartz

4Q13 EPS: Eylea Beat, Pipeline Coming into Focus in 2014

Outperform | **Market Cap:** \$29,579.2M | **Price:** \$304.00 | **Price Target:** \$355.00 | **Methodology:** sum-of-the-parts DCF analysis

• **Bottom Line:** This morning REGN reported 4Q13 ~\$610MM/\$0.86 in revenues/EPS versus our and consensus estimates of ~\$560MM/\$1.01 and ~\$572MM/\$1.00. On a Non-GAAP basis however, REGN's 4Q13 EPS of \$2.24 beat our and consensus estimates of \$2.01 and \$2.07. We remain positive on REGN shares in a catalyst-rich

2014 which entails various Alirocumab data readouts, Duplimumab (Atopic Dermatitis) data in 2Q14, and an Eylea (Diabetic Macular Edema) PDUFA on August 18. **Reiterate OP and \$355 PT in 12 months.**

- 2014 US Eylea revenue guidance of \$1.7-\$1.8B assumes 25% yoy growth,
 - Various Alirocumab (PCSK9) Phase III readouts are expected in mid-14,
 - Other investments in a PDGF-R/anti-VEGF combo-mAb, an immuno-oncology product, and Irish manufacturing facilities
 - Published 2.12.14, intraday.
 - **2014E EPS/REV:** \$6.23 / \$2,680.5 → \$4.70 / \$2,731.1
- Revenues in MM.*

WellCare Health Plans, Inc. (WCG) | Ana Gupte, Ph.D.

4Q13: \$0.06 EPS Miss; 2014 EPS Guidance Below Consensus

Market Perform | **Market Cap:** \$2,737.7M | **Price:** \$62.22 | **Price Target:** \$72.00

- **Bottom Line:** WCG reported 4Q13 EPS of \$1.09, missing us and consensus by \$0.04 and \$0.06, respectively. The EPS miss was driven by (1) Worse-than-expected Medicare Advantage (MA) Medical Loss Ratio (MLR); (2) Worse-than-expected Medicaid MLR; (3) SG&A ratio miss; and (4) Higher-than-expected tax rate offset by better-than-expected Part D MLR, with share count coming roughly in line with expectations. 2014 preliminary EPS guidance of \$3.74-\$4.05 is substantially below our and consensus estimates of \$4.88 and \$5.88, respectively, primarily due to higher tax rate driven by ACA fees' impact. Conference call is at 8:30 a.m. EST with 1-212-231-2915 as dial-in.
- Adjusted 4Q13 EPS of \$1.09 came in \$0.04 and \$0.06 below our and consensus estimates driven by Consolidated MLR coming in worse than expected by 20 bps at 87.3%.
- EPS miss vs. consensus would have been reduced to \$0.03 if the tax rate would have come in line with expectations.
- Total health membership of 2.05MM was lower than expected.
- 2014 preliminary EPS guidance of \$3.74-\$4.05 is substantially below our and consensus estimates of \$4.88 and \$5.88, respectively, primarily due to higher tax rate driven by ACA fees' impact.
- Conference call is at 8:30 a.m. EST with 1-212-231-2915 as dial-in.
- Published 2.12.14.

Research Previews

February 13 – AdCom – POSTPONED due to weather

February 13 – Earnings – Before the Open

ACOR – OP – Marko Kozul

Close: \$30.96, Mkt Cap: \$989M

- 4Q13A EPS/Rev: \$0.15/ \$84.6M
- 4Q13E Leerink EPS/Rev: \$0.00/ \$92.0M
- 4Q13E Street EPS/Rev: \$0.18 / \$90.9M
- 2014E Leerink EPS/Rev: \$0.68 / \$378.0M
- 2014E Street EPS/Rev: \$0.59 / \$369.8M
- **CC:** 8:30am EST; **Dial-in:** 800 299-9086, **Access Code:** 31157384

SHPG – OP – Jason Gerberry

Close: \$156.08, Mkt Cap: \$17,284M

- 4Q13E Leerink EPS/Rev: \$2.04 / \$1,244.0M
- 4Q13E Street EPS/Rev: \$2.08 / \$1,280.2M
- 2014E Leerink EPS/Rev: \$9.00 / \$5,641.0M
- 2014E Street EPS/Rev: \$9.12 / \$5,750.7M

· **CC:** 9:00am EST; **Dial-in:** 866 928-7517, **Access Code:** 46031093

February 13 – Earnings – After the Close

A – OP – Dan Leonard

Close: \$59.89, Mkt Cap: \$16,903M

- F1Q14E Leerink EPS/Rev: \$0.68 / \$1,686.0M
- F1Q14E Street EPS/Rev: \$0.66 / \$1,692.8M
- We recently increased our FY2014-15 revenue and EPS estimates to reflect the improved U.S. budget outlook and improving trends in key end-markets.
- We believe that Agilent's organic growth prospects could narrow the stock's valuation discount to the group multiple.
- F2014E Leerink EPS/Rev: \$3.22 / \$7,045.0M
- F2014E Street EPS/Rev: \$3.19 / \$7,046.1M
- **CC:** 4:30pm EST; **Dial-in:** 855 604-3338, **Access Code:** 31478615

ALNY – OP – Marko Kozul

Close: \$80.44, Mkt Cap: \$958M

- 4Q13E Leerink EPS/Rev: -\$0.51 / \$8.2M
- 4Q13E Street EPS/Rev: -\$0.46 / \$8.8M
- 2014E Leerink EPS/Rev: -\$1.97 / \$32.0M
- 2014E Street EPS/Rev: -\$1.84 / \$37.3M
- **CC:** 4:30pm EST; **Dial-in:** 877 312-7507, **Access Code:** 46682151

February 18 – Earnings – Before the Open

MDT – MP – Danielle Antalffy

Close: \$56.43, Mkt Cap: \$47,102M

- F3Q14E Leerink EPS/Rev: \$0.91 / \$4,184.0M
- F3Q14E Street EPS/Rev: \$0.91 / \$4,150.6M
- F2014E Leerink EPS/Rev: \$3.81 / \$17,099M
- F2014E Street EPS/Rev: \$3.82 / \$17,014M
- **CC:** 8:00am EST; **Dial-in:** NA, **Access Code:** --

February 18 – Earnings – After the Close

BRKR – MP – Dan Leonard

Close: \$21.70, Mkt Cap: \$2,539M

- 4Q13E Leerink EPS/Rev: \$0.29 / \$504.2M
- 4Q13E Street EPS/Rev: \$0.28 / \$502.4M
- 2014E Leerink EPS/Rev: \$0.89 / \$1,867.7M
- 2014E Street EPS/Rev: \$0.88 / \$1,870.6M
- **CC:** 4:45pm EST; **Dial-in:** 877 270-214, **Access Code:** --

NPSP – OP – Joe Schwartz

Close: \$38.27, Mkt Cap: \$790M

- 4Q13E Leerink EPS/Rev: \$0.03 / \$43.9M
- 4Q13E Street EPS/Rev: \$0.03 / \$44.9M
- NPSP recently pre-reported 2013 Gattex sales of ~\$31.5M, which sits at the high end of NPSP's already raised guidance range of \$28-32M.
- For 2014, we estimate Gattex sales of ~\$113M, in the middle of NPSP's guidance of \$110-\$120M, which could be conservative since we assume that Gattex is priced at a ~40% discount in ex-US markets.

- 2014E Leerink EPS/Rev: \$0.46 / \$231.4M
- 2014E Street EPS/Rev: \$0.36 / \$236.2M
- **CC:** 5:00pm EST; **Dial-in:** 800 688-0836, **Access Code:** 71899588

February 19 – Earnings – Before the Open

MDCO – OP – Joe Schwartz

Close: \$31.78, Mkt Cap: \$1,293M

- 4Q13E Leerink EPS/Rev: \$0.21 / \$186.9M
- 4Q13E Street EPS/Rev: \$0.11 / \$183.5M
- We model 4Q13 revenues of \$186.9M (vs. consensus' \$184.2M) and comprised of \$146.8M Angiomax US, \$17.0M Angiomax ROW, \$19.0M in Recothrom, and the rest to Cleviprex and Argatroban.
- We anticipate an update on MDCO's Cangrelor launch plans.
- 2014E Leerink EPS/Rev: \$0.97 / \$785.4M
- 2014E Street EPS/Rev: \$1.00 / \$762.0M
- **CC:** 8:30am EST; **Dial-in:** 866 318-8620, **Access Code:** 76913820

February 19 – Earnings – After the Close

TSRO – OP – Howard Liang

Close: \$31.10, Mkt Cap: \$460M

- 4Q13E Leerink EPS/Rev: -\$0.82 / \$0.0M
- 4Q13E Street EPS/Rev: -\$0.78 / \$0.0M
- 2014E Leerink EPS/Rev: -\$3.28 / \$0.0M
- 2014E Street EPS/Rev: -\$3.33 / \$0.0M
- **CC:** 4:15pm EST; **Dial-in:** 877 853-5334, **Access Code:** --

February 20 – Earnings – Before the Open

ACT – OP – Jason Gerberry

Close: \$189.97, Mkt Cap: \$10,982M

- 4Q13E Leerink EPS/Rev: \$3.09 / \$2,700.0M
- 4Q13E Street EPS/Rev: \$3.05 / \$2,679.8M
- 2014E Leerink EPS/Rev: \$12.79 / \$10,037.0M
- 2014E Street EPS/Rev: \$12.95 / \$10,348.7M
- **CC:** 8:30am EST; **Dial-in:** 877 251-7980, **Access Code:** 50628433

ELOS – OP – Rich Newitter

Close: \$11.20, Mkt Cap: \$309M

- 4Q13E Leerink Cash EPS/Rev: \$0.08 / \$67.4M
- 4Q13E Street Cash EPS/Rev: \$0.08 / \$67.5M
- When ELOS reports 4Q EPS it will likely report a partial (2/3) EBU revenue contribution given that the Syneron Beauty JV closed in early Dec.
- As a result EBU sales/profit will transfer out of the P&L, which reduced our 4QE EBU sales by ~\$3M.
- As a result of that and projected lower y/y PAD sales, we slightly reduced our 4QE sales/EPS on Jan. 31.
- 2014E Leerink Cash EPS/Rev: \$0.43 / \$247.0M
- 2014E Street Cash EPS/Rev: \$0.44 / \$259.8M
- **CC:** 8:30am EST; **Dial-in:** 877 844-6886, **Access Code:** 46590042.

February 20 – Earnings – After the Close

DXCM – MP – Danielle Antalfy**Close: \$41.10, Mkt Cap: \$945M**

- 4Q13E Leerink EPS/Rev: -\$0.08 / \$46.0M
- 4Q13E Street EPS/Rev: -\$0.07 / \$48.9M
- In mid-January, DXCM preannounced solid 4Q13 product revenue sales of ~\$51M (+69% y/y & +20% q/q)—well above both us and the Street.
- That represented the fourth sales beat in a row since the launch of the G4 Platinum in October 2012 but was also somewhat expected based on management commentary on the 3Q13 earnings call.
- DXCM also provided first-time 2014 product revenue guidance of \$205M-\$225M (+31%-43% y/y), which is in-line with us and consensus.
- 2014E Leerink EPS/Rev: -\$0.11 / \$212.7M
- 2014E Street EPS/Rev: -\$0.15 / \$215.6M
- **CC:** 4:30pm EST; **Dial-in:** 888 771-4371, **Access Code:** 36623521

IPXL – MP – Jason Gerberry**Close: \$22.02, Mkt Cap: \$1,399M**

- 4Q13E Leerink EPS/Rev: \$0.07 / \$119.5M
- 4Q13E Street EPS/Rev: \$0.04 / \$118.3M
- 2014E Leerink EPS/Rev: \$0.61 / \$519.0M
- 2014E Street EPS/Rev: \$0.64 / \$523.4M
- **CC:** 4:30pm EST; **Dial-in:** 877 356-3814, **Access Code:** 47654631

MDRX – OP – Dave Larsen**Close: \$16.57, Mkt Cap: \$1,624M**

- 4Q13E Leerink EPS/Rev: \$0.04 / \$339.9M
- 4Q13E Street EPS/Rev: \$0.08 / \$345.2M
- In an 8-K filed in mid-January, mgmt highlighted that it expects to grow non-GAAP revenue 5-8% per year from 2014-16, and adjusted EBITDA at 18-22% per year over the same time frame.
- The top-line growth projections are ahead of our +2% y/y growth in 2014E and +5% y/y growth in 2015E, and the EBITDA growth assumptions appear excellent in our view.
- 2014E Leerink EPS/Rev: \$0.35 / \$1,395.1M
- 2014E Street EPS/Rev: \$0.44 / \$1,432.8M
- **CC:** 4:30pm EST; **Dial-in:** 877 303-0543, **Access Code:** 11273737

VCRA – MP – Dave Larsen**Close: \$16.62, Mkt Cap: \$608M**

- 4Q13E Leerink EPS/Rev: \$0.02 / \$28.5M
- 4Q13E Street EPS/Rev: \$0.02 / \$28.6M
- 2014E Leerink EPS/Rev: \$0.16 / \$116.8M
- 2014E Street EPS/Rev: \$0.18 / \$117.2M
- **CC:** 5:00pm EST; **Dial-in:** 877 280-4958, **Access Code:** 62858866

Previous Notes**February 12**

[Medical Supplies and Devices/Hemophilia Physician Survey: BAX Share Loss Likely in Line with Estimates](#), Danielle Antalfy

[A/Raising Estimates and PT on Improved Outlook/Outperform](#), Dan Leonard

[HSIC/Strategic Acquisitions Continue to Fuel Above Market Growth/Market Perform](#), David Larsen

[NVS/Meetings with Management Highlight Upside Opportunities in 2014/15/Outperform](#), Seamus Fernandez

[SGEN/Adcetris Sales Continue Sequential Growth Trends/Outperform](#), Howard Liang

OMI/New CFO Taking the Right Long-Term Strategic Steps/Market Perform, David Larsen
 PRGO/Post F2Q Model Update; Remain MP Following Mixed 2Q Results/Market Perform, Jason Gerberry

Updated Models: A - Model, AET - Model, IPH FP - Model, MNK - Model, OMI - Model, PRGO - Model, RCPT - Model, REGN - Model, SGEN - Model

2014 Key Controversies

Specialty Pharmaceuticals/2014 Roadmap for Specialty/Generic Pharma, Jason Gerberry
 Biotechnology/Key Controversies and Mgmt. Questions for Our Universe of Small-cap Biotechs, Joe Schwartz
 Biotechnology/Key Controversies and Mgmt Questions for Our Universe of Mid/Large Cap Biotechs, Joe Schwartz
 Managed Care/Top Questions for Company Managements at Upcoming Investor Conferences, Ana Gupte
 LLY/2014 Guidance Mixed but No Change to Our Valuation; Alimta Decision the Key/Outperform, Seamus Fernandez

White Papers

Specialty Pharmaceuticals/ Generics/Future of Respiratory Generics - Next Major Generic Product Class, Jason Gerberry, JD
 Medical Devices-Orthopedics/The Future Of Growth & Innovation In US Extremities Ortho Reconstruction, Rich Newitter
 Biotechnology/Future of Dynamic Multiple Sclerosis Landscape, Marko Kozul, M.D.
 Healthcare IT & Distribution/The Future of HCIT Population Health Management, Dave Larsen
 Life Science Tools and Diagnostics/The Future of DNA Sequencing, Dan Leonard - Life Science Tools and Diagnostics
 Biopharma/Immuno-Oncology: The Future of Cancer Treatment Is Now, Seamus Fernandez
 Biopharma/Future of Orphan Drugs: Neuro Nirvana, Joseph P. Schwartz - Biotechnology
 Biopharma/Future of Hepatitis C Treatment, Howard Liang, Ph.D. - Biotechnology
 Medical Devices-Cardiology/Future of Atrial Fibrillation, Danielle Antalffy - Medical Devices

Deep Dive Analyses

BMRN/Deep Dive on BMN111: Compelling Logic/Early Efficacy Warrant Investor Attention/Outperform, Joseph Schwartz
 DYAX/Deep Dive on DX2930: Value Warranted for Novel HAE Monoclonal Antibody/Outperform, Joseph Schwartz
 SHPG/Deep Dive on Ph. III Pipe; Feedback on Lifitegrast Surprisingly Constructive/Outperform, Jason Gerberry

Recent Surveys

Medical Supplies and Devices/Hemophilia Physician Survey: BAX Share Loss Likely in Line with Estimates, Danielle Antalffy
 AGN/4Q:13 Cosmetic Survey Highlights Stable Growth Trends, Cont'd AGN Strength/Market Perform, Seamus Fernandez
 Medical Devices-Orthopedics/Hip/Knee Survey Highlights 4Q Seasonality & Possible Positive Sign for 1H14, Richard Newitter
 EW/TAVR Survey Suggests Weak 4Q13, Supports Long-Term Market Potential/Outperform, Danielle Antalffy
 Pharmaceuticals/ Major/MEDACorp Diabetes Survey: Solid SGLT2 Prospects & A Tough Januvia (MRK) Outlook, Seamus Fernandez
 Life Science Tools and Diagnostics/Survey Offers Mixed Feedback on Forthcoming Sequencing Demand, Dan Leonard
 Managed Care/Commercial Insurance Survey Points to Unprecedented Price Hardening for 2014, Ana Gupte
 HPTX/Survey Highlights Strong Ravicti Uptake and Evolving Dynamics of UCD Market/Outperform, Joe Schwartz
 FLDM/Survey Mixed but Stem Cell Play Supports Higher Price Target/Market Perform, Dan Leonard
 FRX/Linzess Survey Supports Our >\$1B Linzess Estimate for F2019/Outperform, Seamus Fernandez
 Healthcare IT & Distribution/Ambulatory Survey Shows Integration with Hospital is Key for Large Practices, Dave Larsen

[NPSP/Natpara Survey Exceeds Our Expectations; Increasing PT on Greater hypoPTH Share/Outperform](#), Joe Schwartz

[SLXP/Upgrading to OP; IBS Survey + Prospects for Favorable Xifaxan Label/Outperform](#), Jason Gerberry

Upcoming Healthcare Events

Regulatory Events

2/13 – AdCom – POSTPONED due to weather

2/14: FDA AdCom: Ophthalmic Devices

2/20: FDA AdCom: Anesthesiology and Respiratory Therapy Devices

Medical Meetings

2/12-14: International Stroke Conference

2/12-15: Advances in Genome Biology and Technology

2/19-21: Generic Pharmaceutical Association

Corporate Events

2/13: MOH Investor Day

Disclosures Appendix

Analyst Certification

Each analyst certifies that the views expressed in this report accurately reflect their views and that no part of their compensation was, is, or will be directly related to the specific recommendation or views contained in this report.

Distribution of Ratings/Investment Banking Services (IB) as of 12/31/13				
Rating	Count	Percent	IB Serv./Past 12 Mos.	
			Count	Percent
BUY [OP]	118	64.50	30	25.00
HOLD [MP]	65	35.50	2	3.00
SELL [UP]	0	0.00	0	0.00

Explanation of Ratings

Outperform (Buy): We expect this stock to outperform its benchmark over the next 12 months.

Market Perform (Hold/Neutral): We expect this stock to perform in line with its benchmark over the next 12 months.

Underperform (Sell): We expect this stock to underperform its benchmark over the next 12 months. The degree of outperformance or underperformance required to warrant an Outperform or an Underperform rating should be commensurate with the risk profile of the company.

For the purposes of these definitions the relevant benchmark will be the S&P 600® Health Care Index for issuers with a market capitalization of less than \$2 billion and the S&P 500® Health Care Index for issuers with a market capitalization over \$2 billion.

Important Disclosures

This information (including, but not limited to, prices, quotes and statistics) has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice. This is provided for information purposes only and should not be regarded as an offer to sell or as a solicitation of an offer to buy any product to which this information relates. The Firm, its officers, directors, employees, proprietary accounts and affiliates may have a position, long or short, in the securities referred to in this report, and/or other related securities, and from time to time may increase or decrease the position or express a view that is contrary to that contained in this report. The Firm's salespeople, traders and other professionals may provide oral or written market commentary or trading strategies that are contrary to opinions expressed in this report. The Firm's proprietary accounts may make investment decisions that are inconsistent with the opinions expressed in this report. The past performance of securities does not guarantee or predict future performance. Transaction strategies described herein may not be suitable for all investors. Additional information is available upon request by contacting the Editorial Department at One Federal Street, 37th Floor, Boston, MA 02110.

Like all Firm employees, analysts receive compensation that is impacted by, among other factors, overall firm profitability, which includes revenues from, among other business units, Institutional Equities, and Investment Banking. Analysts, however, are not compensated for a specific investment banking services transaction.

MEDACorp is a network of healthcare professionals, attorneys, physicians, key opinion leaders and other specialists accessed by Leerink and it provides information used by its analysts in preparing research.

Leerink Consulting LLC, an affiliate of Leerink Partners, is a provider of evidence-based strategy and consulting to the healthcare industry.

For price charts, statements of valuation and risk, as well as the specific disclosures for covered companies, client should refer to <https://leerink2.bluematrix.com/bluematrix/Disclosure2> or send a request to Leerink Partners Editorial Department, One Federal Street, 37th Floor, Boston, MA 02110.

©2014 Leerink Partners LLC. All rights reserved. This document may not be reproduced or circulated without our written authority.